FDA Approves Mepolizumab for COPD

FDA Approves Mepolizumab for COPD

(MedPage Today) -- The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) antagonist stipulates use...

GSK drug's new approval sets up competition with Dupixent

Today's biotech news includes Novo's marketing push with telehealth, FDA rec for a new strain for Covid vaccines, and more.

GSK claims first approval for Nucala in COPD

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent

GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med

GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year. The post GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med appeared first on MedCity News.

US Approves GSK’s Lung Disease Drug, Fueling Rivalry With Sanofi

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

Study Highlights Real-World Dupilumab Experiences for Individuals with COPD

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.